Dr Reddy’s partners with Takeda to distribute Qdenga dengue vaccine in India
Dr Reddy’s Laboratories will promote and distribute Takeda’s Qdenga dengue vaccine in India, aiming to expand access to preventive care through doctor and healthcare-institution engagement. The vaccine follows a two-dose schedule.
What happened
Dr. Reddy’s Laboratories · Dr Reddy’s Laboratories partnered with Takeda to promote and distribute Qdenga dengue vaccine in India, targeting the emerging
Key facts
- two-dose schedule
What changed
Dr Reddy’s Laboratories partnered with Takeda to promote and distribute Qdenga dengue vaccine in India, targeting the emerging preventive healthcare market through improved awareness, access, affordability and engagement with doctors and healthcare institutions.
Why this matters
Dr Reddy’s gains a physician- and hospital-led route to scale Qdenga’s two-dose rollout in India’s private preventive-care market.
What to watch
- Qdenga availability, price points and initial hospital/pharmacy coverage across major Indian cities.
- Physician guidance and real-world adoption patterns for different age groups and prior-dengue-exposure profiles.
- Second-dose completion rates and appointment-reminder enrollment.
- Dengue case trends and monsoon forecasts, which could increase preventive-vaccine interest.
- Inclusion in insurer, employer or subscription-health reimbursement programs.